🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Lanzhou University Second Hospital clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Lanzhou University Second Hospital as lead sponsor. Synced 26 Sep 2026
5Current trials
2Recruiting now
0Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Lanzhou University Second Hospital is the lead sponsor of 5 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Observational. The most-studied condition is Unexplained Pregnancy Loss.

ClinicalTrials.gov trials by status

  • Recruiting240%
  • Not yet open120%
  • Active, closed120%
  • By invitation120%

Trials by phase

  • Observational360%
  • Not applicable240%
01

Clinical trials sponsored by Lanzhou University Second Hospital

5 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Effect of Intrauterine Insemination on Subsequent Pregnancy Outcomes in Couples With Unexplained Pregnancy Loss: A Multicenter, Open-label, Randomized Controlled Trial
NCT07759609 · ClinicalTrials.gov ↗ · Unexplained Pregnancy Loss
Not applicable Recruiting 2026-01 China
Effect of Negative Pressure Suction on Fluid Absorption and Infection in Flexible Ureteroscopy
NCT07492147 · ClinicalTrials.gov ↗ · Kidney Stones
Observational Recruiting 2026-03 China
Effects of Enhanced External Counterpulsation Combined With Cardiac Rehabilitation in Patients With Atrial Fibrillation
NCT07058987 · ClinicalTrials.gov ↗ · Atrial Fibrillation (AF), Heart Failure (HF), Cardiac Rehabilitation
Not applicable Not yet open 2025-07 China
Clinical Validation of a Blood Loss Monitoring System
NCT07617428 · ClinicalTrials.gov ↗ · Intraoperative Blood Loss
Observational By invitation 2025-09 China
3D-ASL and TDD-MRI for True Progression and Pseudoprogression After Glioma Surgery
NCT07687277 · ClinicalTrials.gov ↗ · Glioma, Brain Neoplasms
Observational Active, closed 2024-03 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Conditions in Lanzhou University Second Hospital trials

8 conditions
Unexplained Pregnancy Loss1Atrial Fibrillation (AF)1Heart Failure (HF)1Cardiac Rehabilitation1Kidney Stones1Glioma1Brain Neoplasms1Intraoperative Blood Loss1
03

By trial register

RegisterTrialsRecruiting
Clinical trials in China52

A trial with sites in more than one country appears in each of those registers.

04

Questions about Lanzhou University Second Hospital trials

How many clinical trials does Lanzhou University Second Hospital sponsor?

Lanzhou University Second Hospital is the lead sponsor of 5 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Lanzhou University Second Hospital trials recruiting?

Yes. 2 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.